

10 Oct 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Pfizer takes on AstraZeneca and Merck & Co in prostate cancer; AstraZeneca's gene therapy acquisition; ex-Sanofi partnering head joins AI start-up; Shionogi and Medicines Patent Pool strike deal for oral COVID antiviral; and Intercept sticks with NASH plans despite missed endpoint.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 7 October 2022, including: [Pfizer Inc.](#) takes on [AstraZeneca PLC](#) and [Merck & Co., Inc.](#) in prostate cancer; AstraZeneca's gene therapy acquisition; ex-[Sanofi](#) partnering head joins AI start-up; [Shionogi & Co. Ltd.](#) and [Medicines Patent Pool \(MPP\)](#) strike deal for oral COVID antiviral; and [Intercept Pharmaceuticals, Inc.](#) sticks with NASH plans despite missed endpoint.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Pfizer's Talzenna Takes On Top Dog Lynparza In Prostate Cancer](#)" - Scrip, 4 Oct, 2022.)

(Also see "[AstraZeneca's LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope](#)" - Scrip, 4 Oct, 2022.)

(Also see "[Ex-Sanofi Partnering Chief Wants AI Start-Up Owkin To Be Industry Leader](#)" - Scrip, 4 Oct, 2022.)

(Also see "[*Shionogi's Oral COVID Drug Set For Global Access Through MPP*](#)" - Scrip, 4 Oct, 2022.)

(Also see "[*Intercept Not Changing NDA Refiling Plans After OCA Misses NASH Cirrhosis Endpoint*](#)" - Scrip, 30 Sep, 2022.)

[Click here to explore this interactive content online](#) ✨